Welcome to our dedicated page for Harvard Apparatus Regenerative Technology news (Ticker: HRGN), a resource for investors and traders seeking the latest updates and insights on Harvard Apparatus Regenerative Technology stock.
Harvard Apparatus Regenerative Technology, Inc. (OTCQB: HRGN) is a clinical-stage biotechnology company that reports it is developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs. News about HRGN often centers on its cell-therapy platform, which uses a patient’s own stem cells to regenerate and restore function to damaged organs, and on its lead product candidate, the Cellspan Esophageal Implant.
Company updates have highlighted clinical milestones, including FDA approval of a phase one and phase two clinical trial to study repair of esophageal damage in adults, activation of Mayo Clinic and the University of Michigan as clinical trial sites, and engagement of IQVIA as contract research organization. HRGN’s news flow also covers collaborations, such as a partnership with the Children’s Hospital Capital Institute of Pediatrics in Beijing, China to develop treatments for Esophageal Atresia, a research agreement with the McGowan Institute for Regenerative Medicine to study colon repair after colectomy, and a Sponsored Research Agreement with a Yale School of Medicine physician to explore uterine tissue repair.
Investors following HRGN can also find announcements about financing transactions, including private placements and PIPE financings intended to support clinical development and pipeline expansion, as well as updates on the company’s longevity product business operated through a Hong Kong subsidiary. In addition, the company’s news has described its reported world’s first successful regeneration of the esophagus in a patient with esophageal cancer and related scientific publications.
This news page aggregates these types of developments, providing a single location for company-issued financial results, clinical and research updates, collaboration announcements and capital markets activity related to Harvard Apparatus Regenerative Technology.
Harvard Apparatus Regenerative Technology (HRGN) has announced a strategic partnership with the Capital Institute of Pediatrics in Beijing, China, focusing on developing treatments for Esophageal Atresia (EA) using their Cellspan Esophageal Implant (CEI) product candidate. The collaboration aims to conduct Investigator Initiated Trials (IITs) to evaluate CEI's safety and efficacy in treating EA. The partnership combines HRGN's regenerative medicine technology with the institute's pediatric expertise to accelerate regulatory approval and improve patient outcomes.
Harvard Apparatus Regenerative Technology (OTCQB: HRGN) has appointed Mao Zhang as an independent director to its Board of Directors. Zhang, the Founder and CEO of StellarS Capital, brings over 15 years of experience in financial markets, including hedge fund and private equity expertise. This appointment aims to strengthen the company's business innovation, strategy, and finance areas.
Jerry He, chairman of Harvard Apparatus Regenerative Technology, expressed confidence that Zhang's deep business and investment experience will be instrumental in pursuing the company's mission to address unmet patient needs. Zhang, in turn, stated his enthusiasm for joining the board at this important stage of clinical development, highlighting the company's potential to develop novel cell therapies that could change and extend patients' lives through regenerated organs.
Harvard Apparatus Regenerative Technology (OTCQB: HRGN) has secured a $5 million financing through a private placement of shares to a new investor. The funds will accelerate the clinical development of HRGN's lead product, the HRGN Esophageal Implant (BEI). The FDA has approved a ten-patient phase one and phase two clinical trial to study esophageal repair in adults affected by cancer or injury. There's potential to expand the trial to include pediatric subjects with esophageal birth defects. The private placement involves the sale of 1,388,888 shares at $3.60 per share. CEO Jerry He expressed enthusiasm about the new strategic investor and the opportunity to advance HRGN's clinical trials and pipeline development.
Harvard Apparatus Regenerative Technology (OTCQB: HRGN) has reported its first quarter 2024 financial results and recent business highlights. The company, which is developing organ regeneration technology, entered into a $1.5 million PIPE financing agreement that closed on April 15, 2024. Additionally, it received $0.5 million in convertible debt from its CEO in February 2024.
For Q1 2024, HRGN reported a net loss of $2.0 million, or $0.15 per share, an improvement from the $3.0 million loss, or $0.24 per share, in Q1 2023. This was mainly due to a $1.5 million share-based compensation expense incurred in Q1 2023, which was not repeated in 2024. However, increased preclinical and clinical trial activities in Q1 2024 offset some of the gains.
As of March 31, 2024, the company had $0.3 million in operating cash. It used $1.0 million in operational cash during the quarter and raised $0.3 million through financing activities. The company also reported a $0.5 million debt financing from a related party.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.